Intercure Ltd.
corporate_fare Company Profile
Intercure Ltd. (NASDAQ:INCR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for INCR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-08, rated 8/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for INCR spans 6-K, 6-K/A, 20-F.
Recent high-impact activity:
- InterCure Regains Nasdaq Compliance, Averting Delisting Threat
- InterCure Corrects Private Placement Pricing to $4.71/Unit After Reverse Split
- InterCure Finalizes $5M Private Placement at $2.918/Unit with CEO Participation Pending Approval
- InterCure Finalizes NIS 230M (~US$77M) War-Damages Settlement
- InterCure Finalizes $77M War Damages Settlement, Accelerates Nir Oz Rebuild
Financial Snapshot
Insider Transactions
INCR files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.